The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Open accessAbstract
BACKGROUND: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. METHODS: We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St. George's Respiratory Questionnaire, both assessed over a 52-week period. RESULTS: A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo. The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1 and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2. In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P=0.67); in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P=0.005). The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.).
Overview
CoChat Summary
TL;DR
This paper reports two replicate 52-week phase 3 randomized trials showing that nintedanib slowed the decline in forced vital capacity in idiopathic pulmonary fibrosis. Diarrhea was common, but discontinuation due to study medication occurred in less than 5% of patients.
Key findings
- In INPULSIS-1, the adjusted annual rate of change in FVC was -114.7 ml with nintedanib vs -239.9 ml with placebo; the between-group difference was 125.3 ml (95% CI, 77.7 to 172.8; P<0.001).
- In INPULSIS-2, the adjusted annual rate of change in FVC was -113.6 ml with nintedanib vs -207.3 ml with placebo; the between-group difference was 93.7 ml (95% CI, 44.8 to 142.7; P<0.001).
- For time to first acute exacerbation, INPULSIS-1 showed no significant difference (HR 1.15, 95% CI, 0.54 to 2.42; P = 0.67), while INPULSIS-2 showed benefit with nintedanib (HR 0.38, 95% CI, 0.19 to 0.77; P = 0.005).
- The most frequent adverse event was diarrhea: 61.5% vs 18.6% in INPULSIS-1 and 63.2% vs 18.3% in INPULSIS-2 for nintedanib vs placebo, respectively; the conclusion states this led to discontinuation in less than 5% of patients.
Methods
- Two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) compared nintedanib 150 mg twice daily with placebo in patients with idiopathic pulmonary fibrosis.
- 1066 patients were randomly assigned in a 3:2 ratio to nintedanib or placebo.
- Primary outcome was the annual rate of decline in forced vital capacity (FVC); key secondary outcomes were time to first acute exacerbation and change in St. George’s Respiratory Questionnaire total score over 52 weeks.
Limitations
- The text does not state formal study limitations.
- Evident from the paper’s own reporting: the effect on acute exacerbation was inconsistent across the two replicate trials (no significant difference in INPULSIS-1, significant benefit in INPULSIS-2).
- Evident from the text: the provided excerpt does not report the full results for the St. George’s Respiratory Questionnaire outcome, so that secondary endpoint cannot be fully summarized from this text alone.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 0 Not checked · 11 Own results and interpretations
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“which led to discontinuation of the study medication in less than 5% of patients.”
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P = 0.005).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
5 more claims
Create a free account to see all 12 claims and every source verdict.
- It may state two separate claims as one. 1
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [192]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“nintedanib, which was originally developed with oncology in mind, for treatment of idiopathic pulmonary fibrosis150.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials investigating these two drugs in patients with IPF have demonstrated only a slowing of disease progression33,34, as measured by forced vital capacity (FVC) and self-reported quality of life (QOL) metrics, and unclear benefit to survival26, making the development of therapies that can restore lung function and reverse the course of disease a priority.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [34]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationThe St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
Song, J. W., Hong, S.-B., Lim, C.-M., Koh, Y., & Kim, D. S. (2011) · European Respiratory Journal · doi:10.1183/09031936.00159709 · Cited by 783
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citation
Cited by
Items 1,701–1,800 of 4,628
Boesch, M., Baty, F., Brutsche, M. H., Tamm, M., Roux, J., Knudsen, L., Gazdhar, A., Geiser, T., Khan, P., & Hostettler, K. (2020) · Respiratory Research · doi:10.1186/s12931-020-01414-z · Cited by 20
Liu, Y., Zhu, Y., Wu, R., Hu, M., Zhang, L., Lin, Q., Weng, D., Sun, X., Liu, Y., & Xu, Y. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-1050 · Cited by 18
Andrejak, C., Cottin, V., Crestani, B., Debieuvre, D., Gonzalez‐Bermejo, J., Morélot‐Panzini, C., Stach, B., Uzunhan, Y., Maître, B., & Rahérison, C. (2020) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2020.11.009 · Cited by 21
Self-citationPneumothorax in patients with idiopathic pulmonary fibrosis: a real-world experience
Yamazaki, R., Nishiyama, O., Gose, K., Saeki, S., Sano, H., Iwanaga, T., & Tohda, Y. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-020-01370-w · Cited by 20
Diagnosis and Management of Fibrotic Interstitial Lung Diseases
Collins, B. F., & Luppi, F. (2021) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2021.03.008 · Cited by 22
Suzuki, Y., Mori, K., Aono, Y., Kono, M., Hasegawa, H., Yokomura, K., Naoi, H., Hozumi, H., Karayama, M., Furuhashi, K., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-98161-y · Cited by 19
Koo, C. W., Larson, N. B., Parris-Skeete, C., Karwoski, R. A., Kalra, S., Bartholmai, B. J., & Carmona, E. M. (2021) · Clinical Radiology · doi:10.1016/j.crad.2021.11.006 · Cited by 20
Wilfong, E. M., & Aggarwal, R. (2021) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x211060907 · Cited by 21
BAL Transcriptomes Characterize Idiopathic Pulmonary Fibrosis Endotypes With Prognostic Impact
Sadeleer, L. D., Verleden, S. E., Schupp, J. C., McDonough, J. E., Goos, T., Yserbyt, J., Bargagli, E., Rottoli, P., Kaminski, N., Prasse, A., et al. (2022) · CHEST Journal · doi:10.1016/j.chest.2021.12.668 · Cited by 27
Anti-fibrotic effects of pharmacologic FGF-2: a review of recent literature
Dolivo, D. (2022) · Journal of Molecular Medicine · doi:10.1007/s00109-022-02194-3 · Cited by 19
Du, W., Zhang, T., Yang, F., Gul, A., Tang, Z., Zhang, H., Jiang, S., Wang, S., & Dong, J. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154187 · Cited by 19
Liver Injury with Nintedanib: A Pharmacovigilance–Pharmacokinetic Appraisal
Raschi, E., Fusaroli, M., Gatti, M., Caraceni, P., Poluzzi, E., & Ponti, F. D. (2022) · Pharmaceuticals · doi:10.3390/ph15050645 · Cited by 20
Yamakawa, H., Toyoda, Y., Baba, T., Kishaba, T., Fukuda, T., Takemura, T., & Kuwano, K. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11133835 · Cited by 23
Diagnosis and management of idiopathic pulmonary fibrosis
Joshi, V. V., & Nagji, Z. (2022) · Prescriber · doi:10.1002/psb.1998 · Cited by 19
Wang, W., Wang, Q., Xu, C., Li, Z., Song, Z., Zhang, Y., Cai, X., Zhang, S., Lian, B., Li, W., et al. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14693 · Cited by 22
“Nintedanib is a tyrosine kinase inhibitor, which can efficiently slow down the progression of idiopathic pulmonary fibrosis (IPF) and has an acceptable tolerability profile.(74) The pembrolizumab-related pneumonitis was significantly improved after adding nintedanib in an advanced NSCLC patient.”
BackgroundDysregulated Cell–Cell Communication Characterizes Pulmonary Fibrosis
Kurche, J. S., Stancil, I. T., Michalski, J. E., Yang, I. V., & Schwartz, D. A. (2022) · Cells · doi:10.3390/cells11203319 · Cited by 19
Xiong, J., Duan, J., Jiang, N., Zhang, C., Zhong, W., Yang, J., Liu, Y., Su, F., Zhou, Y., Li, D., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109339 · Cited by 20
Repurposing digoxin for geroprotection in patients with frailty and multimorbidity
Lee, H., Wilson, D. V., Bunting, K. V., Kotecha, D., & Jackson, T. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101860 · Cited by 20
“, 2017), consistent with large randomised controlled trial data (Richeldi et al., 2014), and only a small number of serious adverse events were reported (oedema, dyspnoea and pulmonary fibrosis)(Justice et al.”
BackgroundFukihara, J., & Kondoh, Y. (2023) · Respiratory Investigation · doi:10.1016/j.resinv.2023.05.007 · Cited by 24
Zhao, R., Xie, B., Wang, X., Zhang, X., Ren, Y., Wang, C., & Dai, H. (2024) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2024.102287 · Cited by 24
Lee, H., Kim, S. Y., Park, Y. S., Choi, S. M., Lee, J. H., & Park, J. (2024) · Scientific Reports · doi:10.1038/s41598-024-59649-5 · Cited by 23
Albendazole ameliorates aerobic glycolysis in myofibroblasts to reverse pulmonary fibrosis
Zeng, C., Yue, H., Wang, C., Ju, X., Wang, T., Fu, X., Zhou, Q., Zhang, H., He, L., Yu, J., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05655-0 · Cited by 23
Xu, X., Su, X.-J., Zhang, Y.-N., Zheng, X.-K., Lv, P., & Hu, J. (2015) · Journal of Chromatography B · doi:10.1016/j.jchromb.2015.08.032 · Cited by 19
Reck, M. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.1031218 · Cited by 20
Self-Report Daily Life Activity as a Prognostic Marker of Idiopathic Pulmonary Fibrosis
Leuchte, H. H., Mernitz, P., Baezner, C. J., Baumgartner, R., von Wulffen, W., Neurohr, C., & Behr, J. (2015) · Respiration · doi:10.1159/000441302 · Cited by 17
Adherence to guidelines in idiopathic pulmonary fibrosis: a follow-up national survey
Cottin, V., Bergot, E., BOURDIN, A. A., Cadranel, J. L., Camus, P., Crestani, B., Dalphin, J., Delaval, P., Dromer, C., Israël‐Biet, D., et al. (2015) · ERJ Open Research · doi:10.1183/23120541.00032-2015 · Cited by 19
Self-citationRaghu, G. (2017) · European Respiratory Journal · doi:10.1183/13993003.02384-2016 · Cited by 19
Self-citationDiffuse parenchymal lung disease
Tomassetti, S., Ravaglia, C., & Poletti, V. E. (2017) · European Respiratory Review · doi:10.1183/16000617.0004-2017 · Cited by 18
Tamò, L., Simillion, C., Hibaoui, Y., Féki, A., Gugger, M., Prasse, A., Jäger, B., Goldmann, T., Geiser, T., & Gazdhar, A. (2017) · Stem Cell Reviews and Reports · doi:10.1007/s12015-017-9790-9 · Cited by 22
Mortality from idiopathic pulmonary fibrosis: a temporal trend analysis in Brazil, 1979-2014
Algranti, E., Saito, C. A., Silva, D. R. M. E., Carneiro, A. P. S., & Bussacos, M. A. (2017) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37562017000000035 · Cited by 22
Hammond, M., Clark, A., Cahn, A. P., Chilvers, E. R., Fraser, W. D., Livermore, D. M., Maher, T. M., Parfrey, H., Swart, A. M., Stirling, S., et al. (2018) · Trials · doi:10.1186/s13063-018-2453-6 · Cited by 20
Hutchinson, J. P., Hubbard, R., & Raghu, G. (2019) · European Respiratory Journal · doi:10.1183/13993003.00023-2019 · Cited by 20
“In people with idiopathic pulmonary fibrosis (IPF), treatment with both Pirfenidone and Nintedanib has been shown to reduce the rate of disease progression (1, 2), whereas historical use of immunosuppression was shown in the landmark PANTHER study to be harmful (3).”
BackgroundSelf-citationIdiopathic pulmonary fibrosis: the radiologist’s role in making the diagnosis
Mohning, M. P., Richards, J. C., & Huie, T. J. (2019) · British Journal of Radiology · doi:10.1259/bjr.20181003 · Cited by 23
Kangfuxin Oral Liquid Attenuates Bleomycin-Induced Pulmonary Fibrosis via the TGF-β1/Smad Pathway
Yao, H., Wei, S., Xiang, Y., Wu, Z., Liu, W., Wang, B., Li, X., Xu, H., Zhao, J., & Gao, Y. (2019) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2019/5124026 · Cited by 22
Keller, S. P. (2020) · Annals of Cardiothoracic Surgery · doi:10.21037/acs.2019.12.03 · Cited by 21
Ji, K., Jian-ling, M., Liangmin, W., Li, N., Dong, S., & Li-qing, S. (2020) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2020/1752387 · Cited by 22
“Yet, randomized trials have identified some drugs were potentially ineffective or harmful [5, 6], whereas only two, pirfenidone and nintedanib, were proved to be effective disease-modifying therapies for IPF [7, 8].”
BackgroundPulse oximetry saturation can predict prognosis of idiopathic pulmonary fibrosis
Takei, R., Yamano, Y., Kataoka, K., et al. (2020) · Respiratory Investigation · doi:10.1016/j.resinv.2019.12.010 · Cited by 19
Kim, J. S., Steffen, B. T., Podolanczuk, A. J., Kawut, S. M., Noth, I., Raghu, G., Michos, E. D., Hoffman, E. A., Axelsson, G. T., Guðmundsson, G., et al. (2020) · American Journal of Epidemiology · doi:10.1093/aje/kwaa168 · Cited by 17
Self-citationTang, W., Yu, T., Dong, T., et al. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.05.557 · Cited by 19
Xie, T., Kulur, V., Liu, N., Deng, N., Wang, Y., Rowan, S. C., Yao, C., Huang, G., Liu, X., Taghavifar, F., et al. (2021) · Science Advances · doi:10.1126/sciadv.abg6005 · Cited by 24
Self-citationMajewski, S., Szewczyk, K., Jerczyńska, H., Miłkowska-Dymanowska, J., Białas, A. J., Gwadera, Ł., & Piotrowski, W. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.760776 · Cited by 22
Yang, C.-C., Chen, C., Kuo, Y., Ko, C., Wu, W.-J., Liang, C.-H., Yun, C., & Huang, W. (2022) · Diagnostics · doi:10.3390/diagnostics12041002 · Cited by 22
Fernandez, R. J., Gardner, Z., Slovik, K. J., Liberti, D. C., Estep, K. N., Yang, W., Chen, Q., Santini, G. T., Perez, J. V., Root, S., et al. (2022) · eLife · doi:10.7554/elife.64430 · Cited by 20
Sang, L., Guo, X., Fan, H., Shi, J., Hou, S., & Lv, Q. (2022) · Cells · doi:10.3390/cells11152322 · Cited by 21
Olodaterol shows anti‐fibrotic efficacy in in vitro and in vivo models of pulmonary fibrosis
Herrmann, F. E., Wollin, L., Wirth, J., Gantner, F., Lämmle, B., & Wex, E. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13982 · Cited by 23
Kanaan, R., & Strange, C. (2017) · European Respiratory Review · doi:10.1183/16000617.0061-2017 · Cited by 21
Targeting anti-fibrotic pathways in Crohn’s disease – The final frontier?
Ma, C., Jairath, V., Click, B. H., Hirota, S. A., Lu, C., Parker, C. E., & Rieder, F. (2019) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2019.02.005 · Cited by 20
Weber, A., Müller, I., Büchi, A. E., & Guler, S. A. (2023) · Chronic Respiratory Disease · doi:10.1177/14799731231196582 · Cited by 21
A new era in the treatment of progressive fibrosing interstitial lung diseases
Denis, A., Tsiri, P., Guiot, J., & Τzouvelekis, Α. (2025) · Breathe · doi:10.1183/20734735.0259-2024 · Cited by 38
Time for Prevention of Idiopathic Pulmonary Fibrosis Exacerbation
Richeldi, L. (2015) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201504-210aw · Cited by 21
Self-citationKing, C. S., & Nathan, S. D. (2016) · CHEST Journal · doi:10.1016/j.chest.2016.04.034 · Cited by 18
Idiopathic interstitial pneumonia-associated pulmonary hypertension: A target for therapy?
Nathan, S. D., Behr, J., Cottin, V., Collard, H. R., Hoeper, M. M., Martínez, F. J., & Wells, A. U. (2016) · Respiratory Medicine · doi:10.1016/j.rmed.2016.11.003 · Cited by 20
Self-citationYu, W. S., Lee, J. G., Paik, H. C., Kim, S., Lee, S., Kim, S. Y., Park, M. S., & Haam, S. (2018) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezy170 · Cited by 19
Wijsenbeek, M. S., Bendstrup, E. M., Valenzuela, C., Henry, M. T., Moor, C. C., Bengus, M., Perjesi, A., Gilberg, F., Kirchgaessler, K.-U., & Vancheri, C. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0845-3 · Cited by 20
Obstacles to early treatment of idiopathic pulmonary fibrosis: current perspectives
Moua, T., & Ryu, J. H. (2019) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s160248 · Cited by 18
T cell Co-Stimulatory molecules ICOS and CD28 stratify idiopathic pulmonary fibrosis survival
Bonham, C. A., Hrusch, C. L., Blaine, K. M., Manns, S. T., Vij, R., Oldham, J. M., Churpek, M. M., Strek, M. E., Noth, I., & Sperling, A. I. (2019) · Respiratory Medicine X · doi:10.1016/j.yrmex.2019.100002 · Cited by 25
Lemieszek, M. K., Rzeski, W., Golec, M., Maćkiewicz, B., Zwoliński, J., Dutkiewicz, J. K., & Milanowski, J. (2020) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2020.110416 · Cited by 20
Riddell, P., Kleinerová, J., Eaton, D. A., Healy, D. G., Javadpour, H., McCarthy, J. F., Nölke, L., Redmond, K., & Egan, J. J. (2020) · European Respiratory Journal · doi:10.1183/13993003.02413-2019 · Cited by 19
Cell Therapy for Idiopathic Pulmonary Fibrosis: Rationale and Progress to Date
Ntolios, P., Steiropoulos, P., Karpathiou, G., Anevlavis, S., Karampitsakos, Τ., Bouros, E., Froudarakis, Μ. E., Bouros, D. E., & Tzouvelekis, A. (2020) · BioDrugs · doi:10.1007/s40259-020-00437-8 · Cited by 20
Wijsenbeek, M. S., Bendstrup, E. M., Valenzuela, C., Henry, M. T., Moor, C. C., Jouneau, S., Fois, A. G., Moran‐Mendoza, O., Anees, S., Mirt, M., et al. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01790-y · Cited by 20
Mergault, C., Lisée, F., Tiroille, V., Magnien, M., Parent, C., Bonda, W. L. M., Sizaret, D., Jaillet, M., Crestani, B., Marchand-Adam, S., et al. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15675 · Cited by 24
Derseh, H. B., Perera, K. U. E., Dewage, S. N. V., Stent, A. W., Koumoundouros, E., Organ, L. A., Pagel, C. N., & Snibson, K. J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.700902 · Cited by 19
“Although two disease retarding drugs have been approved for IPF in 2014, there is no totally effective pharmacologic treatment currently available that cures the disease (King et al., 2014; Richeldi, 2014; Richeldi et al., 2014).”
BackgroundChronic Obstructive Pulmonary Disease Combined with Interstitial Lung Disease
Choi, J. Y., Song, J. W., & Rhee, C. K. (2022) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2021.0141 · Cited by 20
Contemporary Concise Review 2021: Interstitial lung disease
McCarthy, C., & Keane, M. P. (2022) · Respirology · doi:10.1111/resp.14278 · Cited by 21
Cao, M., Gu, L., Guo, L., Liu, M., Wang, T., Zhang, J., Zhang, H., Zhang, Y., Shi, Y., Zhao, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.891448 · Cited by 19
“Although the tyrosine kinase inhibitor can decrease the incidence of AE, there is still no optimal therapy for AE-IPF (2, 25).”
BackgroundLv, Y., Cai, G.-F., Zeng, P.-P., Dhlamini, Q., Chen, L.-F., Chen, J., Lyu, H., Mohammadi, M. M., Ahmadvand, N., Bellusci, S., et al. (2022) · Cells · doi:10.3390/cells11152396 · Cited by 22
Cottin, V., Bonniaud, P., Cadranel, J. L., Crestani, B., Jouneau, S., Marchand-Adam, S., Nunès, H., Wémeau-Stervinou, L., Bergot, E., Blanchard, É., et al. (2022) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2022.100948 · Cited by 25
Self-citationNovel mediators of idiopathic pulmonary fibrosis
Saito, S., Deskin, B., Rehan, M., Yadav, S., Matsunaga, Y., Lasky, J. A., & Thannickal, V. J. (2022) · Clinical Science · doi:10.1042/cs20210878 · Cited by 20
Long-Term Safety of Antifibrotic Drugs in IPF: A Real-World Experience
Levra, S., Guida, G., Sprio, A. E., Crosa, F., Ghio, P. C., Bertolini, F., Carriero, V. M. A., Albera, C., & Ricciardolo, F. L. M. (2022) · Biomedicines · doi:10.3390/biomedicines10123229 · Cited by 20
Choi, M. G., Choi, S. M., Lee, J. H., Kim, J., & Song, J. W. (2022) · Respiratory Research · doi:10.1186/s12931-022-02273-6 · Cited by 17
Association between weight loss and mortality in idiopathic pulmonary fibrosis
Kalininskiy, A., Rackow, A. R., Nagel, D. J., Croft, D. P., Minton, H. M., & Kottmann, R. M. (2022) · Respiratory Research · doi:10.1186/s12931-022-02277-2 · Cited by 20
Disparities in Antifibrotic Medication Utilization Among Veterans With Idiopathic Pulmonary Fibrosis
Kaul, B., Lee, J. S., Petersen, L. A., McCulloch, C. E., Rosas, I. O., Bandi, V., Zhang, N., DeDent, A. M., Collard, H. R., & Whooley, M. A. (2023) · CHEST Journal · doi:10.1016/j.chest.2023.02.027 · Cited by 18
Self-citationImproved Survival of IPF patients Treated With Antifibrotic Drugs Compared With Untreated Patients
Platenburg, M. G. J. P., van Moorsel, C. H. M., Wiertz, I. A., van der Vis, J. J., Vorselaars, A. D. M., Veltkamp, M., & Grutters, J. C. (2023) · Lung · doi:10.1007/s00408-023-00628-4 · Cited by 21
Personalized medicine in sarcoidosis: unravelling biomarkers for targeted care
Francesqui, J., Marrades, P., & Sellarés, J. (2023) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000985 · Cited by 18
“Nintedanib is a tyrosine kinase inhibitor that reduces fibrosis progression in patients with IPF and systemic sclerosis-associated ILD [36,37].”
BackgroundInfluentialKacprzak, A., Tomkowski, W. Z., & Szturmowicz, M. (2023) · Diagnostics · doi:10.3390/diagnostics13142354 · Cited by 22
“Anti-fibrotic drugs are used to delay disease progression in IPF [48,49] and other fibrotic lung diseases progressing despite immunomodulatory therapy [50,51].”
BackgroundAnimal models of silicosis: fishing for new therapeutic targets and treatments
Martínez‐López, A., Candel, S., & Tyrkalska, S. D. (2023) · European Respiratory Review · doi:10.1183/16000617.0078-2023 · Cited by 24
Montesi, S. B., Gómez, C. R., Beers, M. F., Brown, R., Chattopadhyay, I., Flaherty, K. R., Garcia, C. K., Gomperts, B. N., Hariri, L. P., Hogaboam, C. M., et al. (2023) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202307-1154ws · Cited by 21
Self-citationWang, X., Goyal, M., Gadhave, D. G., & Gupta, V. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105615 · Cited by 19
Antifibrotic therapy in progressive pulmonary fibrosis: a review of recent advances
Naqvi, M., Hannah, J. R., Lawrence, A., Myall, K. J., West, A., & Chaudhuri, N. (2024) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2024.2375420 · Cited by 22
Quintela-Fandiño, M., Bermejo, B., Zamora, E., Moreno, F., García-Sáenz, J. Á., Pernas, S., Martínez-Jáñez, N., Jiménez, D., Adrover, E., Andrés, R., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1518 · Cited by 23
Children’s Interstitial and Diffuse Lung Disease. Progress and Future Horizons
Deterding, R. R. (2015) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201508-558ps · Cited by 18
Kamio, K., Usuki, J., Azuma, A., Matsuda, K., Ishii, T., Inomata, M., Hayashi, H., Kokuho, N., Fujita, K., Saito, Y., et al. (2015) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2015.03.001 · Cited by 18
“Moreover, nintedanib inhibited lung function decline in IPF patients in a recent phase III clinical trial [7].”
BackgroundSelf-citationHuang, X., Wang, W., Yuan, H., Sun, J., Li, L., Wu, X., Luo, J., & Gu, Y. (2016) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.239.251 · Cited by 19
The safety of new drug treatments for idiopathic pulmonary fibrosis
Fletcher, S., Jones, M. G., Spinks, K., Sgalla, G., Marshall, B. G., Limbrey, R., & Richeldi, L. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1218470 · Cited by 20
Self-citationHamano, Y., Kida, H., Ihara, S., Murakami, A., Yanagawa, M., Ueda, K., Honda, O., Tripathi, L. P., Arai, T., Hirose, M., et al. (2017) · Scientific Reports · doi:10.1038/srep43201 · Cited by 16
Self-citationMojiri-Forushani, H., Hemmati, A. A., Dehghani, M. A., et al. (2017) · Journal of Chinese Integrative Medicine · doi:10.1016/s2095-4964(17)60363-7 · Cited by 18
Kadoch, M. A., Kitich, A., Alqalyoobi, S., LaFond, E., Foster, E. E., Juarez, M. M., Mendez, C., Smith, T. W., Wong, G. B., Boyd, W. D., et al. (2018) · Respiratory Medicine · doi:10.1016/j.rmed.2018.02.017 · Cited by 19
Chung, J. H., & Goldin, J. G. (2018) · Lung · doi:10.1007/s00408-018-0143-5 · Cited by 19
Perelas, A., Glennie, J., van Kerkhove, K., Li, M., Scheraga, R. G., Olman, M. A., & Culver, D. A. (2019) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2019.101839 · Cited by 18
“The treatment of idiopathic pulmonary fibrosis (IPF) has been revolutionized by the introduction of antifibrotic therapy, but medication intolerance is common and often necessitates dose reduction or discontinuation [1, 2].”
BackgroundMethodPamrevlumab in idiopathic pulmonary fibrosis
Wells, A. U. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30339-x · Cited by 17
Xue, L., Deng, D., Zheng, S., Tang, M., Yang, Z., Pei, H., Chen, Y. X., Yang, T., Liu, K., Ye, H., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112259 · Cited by 19
Majewski, S., Białas, A. J., Buchczyk, M., Gomółka, P., Górska, K., Jagielska-Len, H., Jarzemska, A., Jassem, E., Jastrzębski, D., Kania, A., et al. (2020) · BMC Pulmonary Medicine · doi:10.1186/s12890-020-1162-6 · Cited by 20
Sadeleer, L. D., Goos, T., Yserbyt, J., & Wuyts, W. A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061722 · Cited by 20
“placebo [6], these data were roughly replicated, and an FVC decline <5% was observed”
MethodRictor-targeting exosomal microRNA-16 ameliorates lung fibrosis by inhibiting the mTORC2-SPARC axis
Inomata, M., Kamio, K., Azuma, A., Matsuda, K., Usuki, J., Morinaga, A., Tanaka, T., Kashiwada, T., Atsumi, K., Hayashi, H., et al. (2020) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.112416 · Cited by 20
Self-citationYamagata, A., Arita, M., Tachibana, H., Tokioka, F., Sugimoto, C., Sumikawa, H., Tanaka, T., Yasui, H., Fujisawa, T., Nakamura, Y., et al. (2021) · Respiratory Research · doi:10.1186/s12931-021-01726-8 · Cited by 20
Management of Idiopathic Pulmonary Fibrosis
Salisbury, M. L., & Wijsenbeek, M. S. (2021) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2021.03.004 · Cited by 20
Ranjan, Y., Althobiani, M. A., Jacob, J., Orini, M., Dobson, R., Porter, J. C., Hurst, J. R., & Folarin, A. (2021) · JMIR Research Protocols · doi:10.2196/28873 · Cited by 18
Gudmundsson, E., Zhao, A., Moğulkoç, N., Stewart, I. D., Jones, M. G., van Moorsel, C. H. M., Savaş, R., Brereton, C. J., van Es, H. W., Unat, Ö. S., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101009 · Cited by 21
“In a subanalysis of the patients who would be approved by regulators for receiving antifibrotic medication, the additional eligibility criteria of FVC that was 50% or more of the predicted value and DLco that was 30 to 79% of the predicted value was applied, in agreement with clinical drug trials in IPF [12].”
BackgroundMethodCésar, E. C., López, L. L., Lara, E., Juan, M. V. H.-S., Romero, C. P., Palencia, J. L. R. S., Martín‐Montañez, E., & Garcia‐Fernandez, M. I. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10143167 · Cited by 21
Exposure–safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease
Schmid, U., Weber, B., Sarr, C., & Freiwald, M. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01598-0 · Cited by 18
Metadata
- Authors
- Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., Stowasser, S., Schlenker-Herceg, R., Disse, B., & Collard, H. R.
- Affiliations
- NIHR Southampton Respiratory Biomedical Research Unit (GB)
- University of Washington (US)
- Nippon Medical School (JP)
- Ruhrlandklinik (DE)
- Université de Lyon (FR)
- Michigan Medicine (US)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- NHO Kinki Chuo Chest Medical Center (JP)
- Asan Medical Center (KR)
- McMaster University (CA)
- Cedars-Sinai Medical Center (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Tosei General Hospital (JP)
- Boehringer Ingelheim (Germany) (DE)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2071-2082
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138871107
- Cited by
- 4,654
- References
- 21
- Citations by year
- 2026: 338 · 2025: 372 · 2024: 479 · 2023: 412 · 2022: 429 · 2021: 501 · 2020: 423 · 2019: 350 · 2018: 345 · 2017: 328 · 2016: 293 · 2015: 292 · 2014: 74
- FWCI
- 263.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion, cc-by-nc-nd)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Amgen
- Pfizer
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Celgene
- FibroGen
- Ikaria
- University Hospital Southampton NHS Foundation Trust
- Massachusetts Medical Society
- Royal Brompton and Harefield NHS Foundation Trust
- Galecto
- Veracyte
- National Institute for Health and Care Research (NF-SI-0512-10157)
- Imperial College London
- Shionogi
- Genentech
- Japan Society for the Promotion of Science (24591149)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, idiopathic pulmonary fibrosis, tyrosine kinase inhibitors, forced vital capacity decline, acute exacerbation, St George's Respiratory Questionnaire, drug safety, INPULSIS trials, lung function preservation, adverse events, diarrhea, liver enzymes, proteinuria, thrombocytopenia, neutropenia, antifibrotic therapy
- MeSH terms
- Aged, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Quality of Life, Vital Capacity, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.